Author

Andrew M. Waters

University of CincinnatiORCID 0000-0002-6058-5878Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1

Frequent Co-Authors

Adrienne D. CoxiD· 2 shared Channing J. DeriD· 2 shared Clint A. StalneckeriD· 2 shared Jeffrey A. KlompiD· 2 shared Kirsten L. BryantiD· 2 shared Runying Y. YangiD· 2 shared Wen-Hsuan ChangiD· 2 shared Addison G. StameyiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Adrienne D. CoxORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintAug 11, 2026

Concurrent AXL inhibition enhances RAS and ERK inhibitor efficacy in KRAS-mutant pancreatic and lung cancer

Yan Ming Ching, Shruthi Narayanan, Jeffrey A. Klomp…·Bjoern Papke

This study shows that combining AXL inhibition with RAS or ERK inhibitors enhances efficacy in KRAS-mutant cancers by overcoming resistance mechanisms.

1 citation

humanmouse

𝕏 PostBluesky

Cancer BiologybioRxivPreprintApr 21, 2026

Characterization and therapeutic suppression of KEAP1-NRF2-driven resistance to KRAS inhibitors in pancreatic and lung cancer

Wen-Hsuan Chang, Alec J. Vaughan, Addison G. Stamey…·Channing J. Der

This study identifies KEAP1 loss as a resistance mechanism to KRAS inhibitors in pancreatic and lung cancer and shows that combining glutamine inhibition with KRAS inhibitors can overcome this resistance.

1 citation

humanbulk RNA-seq

𝕏 PostBluesky